Dr. Paul Auwaerter previews the upcoming flu, RSV, and COVID-19 season. Topics: *How will influenza and RSV impact COVID-19 risk? *How COVID-19 subvariants are impacting vaccine efficacy *Outpatient treatments after the loss of a monoclonal antibody *COVID-19 prioritization of treatment *Severity of current subvariants compared to previous variants
Faculty
Clinical Director, Division of Infectious Diseases
Sherrilyn and Ken Fisher Professor of Medicine
Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine